drugset / Trial / NCT02038972

Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss

NCT02038972

Phase 1 Completed 11 enrolled James Baumgartner, MD CBR Systems, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.

Timeline

Start
2013-01
Primary completion
2015-12-11
Completion
2017-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Stem Cells Cell therapy 6e+06 cells/kg Intravenous